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A B S T R A C T   
Human immunodeficiency virus type 1 (HIV-1) is known to provoke microglial immune responses which likely 
play a paramount role in the development of chronic neuroinflammatory conditions and neuronal damage 
related to HIV-1 associated neurocognitive disorders (HAND). In particular, HIV-1 Tat protein is a proin-
flammatory neurotoxin which predisposes neurons to synaptodendritic injury. Drugs targeting the degradative 
enzymes of endogenous cannabinoids have shown promise in reducing inflammation with minimal side effects in 
rodent models. Considering that markers of neuroinflammation can predict the extent of neuronal injury in 
HAND patients, we evaluated the neurotoxic effect of HIV-1 Tat-exposed microglia following blockade of fatty 
acid amid hydrolyze (FAAH), a catabolic enzyme responsible for degradation of endocannabinoids, e.g. anan-
damide (AEA). In the present study, cultured murine microglia were incubated with Tat and/or a FAAH inhibitor 
(PF3845). After 24 h, cells were imaged for morphological analysis and microglial conditioned media (MCM) was 
collected. Frontal cortex neuron cultures (DIV 7–11) were then exposed to MCM, and neurotoxicity was assessed 
via live cell calcium imaging and staining of actin positive dendritic structures. Results demonstrate a strong 
attenuation of microglial responses to Tat by PF3845 pretreatment, which is indicated by 1) microglial changes 
in morphology to a less proinflammatory phenotype using fractal analysis, 2) a decrease in release of neurotoxic 
cytokines/chemokines (MCP-1/CCL2) and matrix metalloproteinases (MMPs; MMP-9) using ELISA/multiplex 
assays, and 3) enhanced production of endocannabinoids (AEA) using LC/MS/MS. Additionally, PF3845’s effects 
on Tat-induced microglial-mediated neurotoxicity, decreased dysregulation of neuronal intracellular calcium and 
prevented the loss of actin-positive staining and punctate structure in frontal cortex neuron cultures. Interest-
ingly, these observed neuroprotective effects appeared to be independent of cannabinoid receptor activity (CB1R 
& CB2R). We found that a purported GPR18 antagonist, CID-85469571, blocked the neuroprotective effects of 
PF3845 in all experiments. Collectively, these experiments increase understanding of the role of FAAH inhibition 
and Tat in mediating microglial neurotoxicity in the HAND condition.  
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1. Introduction 
Combined antiretroviral therapy (cART) has drastically improved 
the outlook for patients infected with human immunodeficiency virus 
type 1 (HIV-1); however, many display neurocognitive impairments 
related to prefrontal cortex function (Cysique et al., 2004; Heaton et al., 
2011), referred to as HIV-associated neurocognitive disorders (HAND) 
(Ellis et al., 2007; Heaton et al., 2011). A significant correlate of HAND 
progression is synaptodendritic damage, suggesting that loss of viable 
structures underlie deficits found in HIV-1 infected patients (Masliah 
et al., 1997). The HIV-1 transactivator of transcription (Tat) is detect-
able in cART treated individuals (Henderson et al., 2019) and acts as a 
potent neurotoxin contributing to the pathogenesis of HAND (Carroll 
and Brew, 2017; King et al., 2006; Rao et al., 2014). Tat directly impacts 
neuronal function through dysregulation of AMPA/NMDA function 
leading to enhanced excitability, and dendritic simplification and loss of 
function (Brailoiu et al., 2008; Fitting et al., 2014; Haughey et al., 2001; 
Longordo et al., 2006; Prendergast et al., 2002). In addition, microglial 
activation by HIV-1 virotoxins drives immune signaling that contributes 
to neuronal damage (Jin et al., 2012; Sheng et al., 2000). Considering 
the innate immune response in the brain occurs shortly after HIV-1 
infection, reducing microglial activity offers a promising strategy for 
altering the progression of HAND. 
Microglia contribute to brain disease through chronic immune acti-
vation, proinflammatory signaling cascades, and immune quiescence 
(Dheen et al., 2007; Perry and Teeling, 2013). Specifically, microglia 
exposed to HIV-1 and/or viral proteins undergo proinflammatory acti-
vation and promote neurotoxic brain conditions (Jin et al., 2012; Liu 
et al., 2013; Sheng et al., 2000). Thus, anti-inflammatory drugs may 
prove useful for treating neurodegenerative conditions, in part, through 
microglia. Cannabinoids elicit anti-inflammatory effects in several dis-
ease models (Nagarkatti et al., 2009) and specifically block proin-
flammatory signaling in microglia (Ashton and Glass, 2007; Ehrhart 
et al., 2005). Therefore, cannabinoids may be an effective treatment 
strategy for slowing and/or blocking neurotoxic inflammation and 
HAND progression. 
Levels of the endogenous cannabinoid ligands, anandamide (N- 
arachidonoylethanolamine, AEA) and 2-arachidonoylglycerol (2-AG), 
are heightened in individuals diagnosed with neurodegenerative disor-
ders and negatively correlate with severity of disease progression (Chen 
et al., 2011; More and Choi, 2015; Pryce et al., 2003). These ligands 
exert their effects primarily via cannabinoid receptors type 1 and 2 
(CB1R and CB2R), but also through other G protein-coupled receptors 
(GPCRs) such as GPR55 and GRP18 (Harkany et al., 2008; Henstridge, 
2012; McHugh, 2012; Ross et al., 2012). Activated microglia express 
CB2Rs, which regulate microglial immune function (Ashton and Glass, 
2007; Ehrhart et al., 2005; Malek et al., 2015), and stimulation of this 
receptor blunts neurotoxic cytokine release mediated by HIV-1 gp120 
protein (Hu et al., 2013). Moreover, GPR55 and GPR18 reduce neuro-
toxicity in organotypic hippocampal cultures likely through modulation 
of microglial activity (Grabiec et al., 2019; Kallendrusch et al., 2013). 
Therefore, the present study proposes to explore further microglial 
cannabinoid receptors and their function in regulating 
neuroinflammation. 
Currently available cannabinoid receptor agonists have limited 
therapeutic use because of their undesirable cannabimimetic side effects 
(Cooper and Haney, 2009; Justinova et al., 2003; Lichtman et al., 1995). 
Conversely, drugs that elevate endogenous cannabinoid signaling show 
promise for use as therapeutics with limited cannabimimetic side effects 
(Booker et al., 2012; Ignatowska-Jankowska et al., 2015; Ignatowska- 
Jankowska et al., 2014). Because endogenous cannabinoids are syn-
thesized and released “on-demand” (Marsicano et al., 2003), inhibiting 
their degradation leads to increased cannabinoid receptor signaling 
locally where their production is elevated (e.g. at sites of brain injury). A 
fatty acid amide hydrolase (FAAH) inhibitor, PF3845, enhances AEA 
content in the central and peripheral nervous systems (Booker et al., 
2012), and supports neuronal survival and attenuate neuroinflammation 
in vivo (Tchantchou et al., 2014). In addition, microglia express both 
FAAH (Tham et al., 2007) and AEA (Carrier et al., 2004; Stella, 2009), 
indicating they are viable cellular targets for FAAH inhibition to in-
crease AEA signaling at cannabinoid receptors. Enzyme inhibitors that 
block endocannabinoid degradation, such as PF3845, affect microglial 
activity. Thus, we hypothesize that FAAH inhibition will elicit microglia- 
mediated protective effects against HIV-1 mediated neurotoxicity. 
To test this hypothesis, the present study evaluates the effects of 
PF3845 on murine microglial-mediated neurotoxicity via live cell cal-
cium imaging and staining of actin positive dendritic structures and 
characterizes microglial changes in morphology using fractal analysis. 
In addition, ELISA/multiplex assays are employed to assess release of 
neurotoxic cytokines/chemokines and matrix metalloproteinases 
(MMPs). Finally, mass spectrometry (LC/MS/MS) was used to quantify 
the levels of endocannabinoids in cultured microglia. Collectively, these 
experiments provide insight into the role of FAAH inhibition and Tat in 
mediating microglial neurotoxicity. 
2. Materials and methods 
2.1. Experimental design 





ANOVA analysis of variance 
cART combined antiretroviral therapy 
CBD cannabidiol 
CB1R cannabinoid receptor type 1 
CB2R cannabinoid receptor type 2 
CID CID-85469571/GPR18 antagonist 
DF fractal dimension 
DIV days in vitro 
FAAH fatty acid amide hydrolase 
GPCR G protein coupled receptor 
GPR18 G protein couple receptor 18 
HAND HIV-associated neurocognitive disorders 
HIV-1 human immunodeficiency virus 1 
KO knockout 
LPS lipopolysaccharide 
MCM microglia-conditioned medium 
MCP-1 monocyte chemoattractant protein 1 
MMP matrix metalloproteinase 
NAGly N-Arachidonylglycine 
ROI region of interest 
SEM standard error of the mean 
SR141 rimonabant/SR141716/CB1R antagonist 
SR144 SR144528/CB2R antagonist 
Tat transactivator of transcription 
THC Δ9-tetrahydrocannabinol 
WT wildtype 
◦C degrees Celsius 
Λ lacunarity  
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sections, including the between-subjects factors and a full description of 
critical variables required for independent replication. All experiments 
were approved by the University of North Carolina at Chapel Hill and 
conducted in accordance with the National Institutes of Health Guide for 
the Care and Use of Laboratory Animals (Council, 2011). 
2.2. Treatments 
Cultured microglia were incubated with HIV-1 Tat1–86 (100 nM; IIIB, 
#1002, ImmunoDx, MA), lipopolysaccharide (LPS; 1 μg/mL; L2880, 
Sigma-Aldrich, MO), PF3845 (100 nM, Dr. Benjamin Cravatt; Scripps, 
CA), the endogenous GPR18 agonist NAGly (100 nM – 10 μM, Tocris, 
UK), the CB2R agonist HU-308 (100 nM; #90086, Cayman, MI), the 
CB1R antagonist SR141716A (SR141, 100 nM, Tocris, UK), the CB2R 
antagonist SR144528 (SR144, 100 nM, Tocris, UK), the selective GPR18 
antagonist CID-85469571 (CID, 100 nM, AOB9837, Aobious, MA), the 
selective GPR55 antagonist ML193 (100–1 μM, Tocris, UK), the MCP-1 
inhibitor bindarit (300 μM; #11479, Cayman, MI), and/or the MMP-9 
inhibitor I (150 nM; #444278, Sigma-Aldrich, MO). Tat 100 nM con-
centration was selected as it produces cellular deficits in vitro compa-
rable to those found in post-mortem tissue samples collected from 
individuals with HAND (El-Hage et al., 2008; El-Hage et al., 2011; 
Kruman et al., 1998; Perry et al., 2010). Tat concentrations in human 
brain tissue have not been determined yet but have been detected 
immunohistochemically and in protein extracts from the brains of sim-
ian immunodeficiency virus (SIV)-infected rhesus macaques with en-
cephalitis (Hudson et al., 2000). Even though the concentrations of Tat 
in the cerebral spinal fluid (CSF) has been reported at around 1.14 nM 
(~16 ng/mL), higher concentrations of Tat could be attainable locally 
within close proximity of HIV-1 infected cells (Westendorp et al., 1995). 
At DIV 14 microglial cultures were incubated with PF3845 or NAGly for 
1 h prior to Tat treatment. Tat was added to cultures and allowed to 
incubate for 24 h before media was collected. Treatment with selective 
inhibitors or receptor antagonists was conducted 1 h or 30 min prior to 
PF3845 treatment, respectively, and were present throughout the 
duration of Tat incubation. GPR18 antagonist CID-85469571 (CID) was 
selected because it has been shown to have 36-fold selectivity compared 
to GPR55 (Rempel et al., 2014). For a positive control experiment DIV 
14 microglial cultures were treated with LPS and 1 h later HU-308 was 
added to the cultures, similar to what has been published previously 
(Presley et al., 2015). After 24 h, MCM was collected for ELISA analysis 
to determine MCP-1/CCL2 and pro-MMP-9/MMP9 levels. 
2.3. Cell culture and conditioned media 
Primary microglial cultures were derived from whole brain punches 
taken from C57BL/6 (Charles River, NC) neonatal mouse pups at post-
natal day 0–1. In addition, for calcium imaging experiments, both FAAH 
wildtype (WT) and FAAH knockout (KO) animals were used to derive 
cultures. These animals were provided by Dr. Aron Lichtman (Virginia 
Commonwealth University, VA). Punches were suspended in DMEM 
(Invitrogen, CA) with fetal bovine serum, and 7.5% sodium bicarbonate, 
in six well ultra-low attachment plates (Sigma-Aldrich, MO) to prevent 
neuronal and astroglial growth. Cells were grown to confluency over 2 
wks (97.5 ± 17.9 cells/mm2) and used for experiments on days in vitro 
(DIV) 14–17. Media was completely changed one day after plating and 
partial media replacement was carried out every 3 d after initial change. 
All drug treatments were diluted in Brainphys culture media (Stemcell 
Technologies, Canada) and collected 24 h following Tat administration. 
Microglia conditioned medium (MCM) was collected through 0.2 μm 
filter before being immediately frozen. Samples were stored at − 20 ◦C 
for no longer than 4 wks and never freeze-thawed more than twice 
before experimental use. Whole MCM was used for ELISA, multiplex, 
and mass spectrometry while 1:4 dilution was used for calcium imaging 
and synaptic integrity experiments. 
Primary neuronal cultures were derived from dissociated frontal 
cortex tissue of embryonic day 16–17 C57BL/6C mice. Frontal cortex 
tissue was dissected from the rostral portion of the neocortex similar to 
the frontal cortex size that has been shown with gene expression markers 
(Cholfin and Rubenstein, 2007). Cultures for calcium imaging were 
prepared as previously described (Hermes et al., 2018). In brief, 
collected tissue was minced and incubated (30 min, 37 ◦C) with trypsin 
(2.5 mg/mL) and DNase (0.015 mg/mL) in HBSS (Invitrogen, CA) and 
centrifuged 2× for 5 min. Cells were then plated on MatTek 35 mm glass 
bottom dishes, coated with poly-L-lysine (Sigma-Aldrich, MO), at a 
concentration of 1 × 105 cells per dish and maintained in neurobasal 
medium (NBM) supplemented with B27 (Invitrogen, CA), 0.5 mM L- 
glutamine, 0.025 mM glutamate at 37 ◦C in a humidified atmosphere 
containing 5% CO2. Calcium imaging experiments were performed on 
neuronal cultures at DIV 7–11 ensuring that rudimentary dendritic/ 
axonal structures were established. Neurons used for synaptic integrity 
experiments were collected in HBSS using papain (0.5 mg/mL, Stemcell 
Technologies, Canada) for dissociation with no centrifugation. Cells 
were plated on glass coverslips (1 × 105 cells per coverslip) and main-
tained in NBM Plus (Invitrogen, CA) with B27 Plus (Invitrogen, CA), 0.5 
mM L-glutamine, 0.025 mM glutamate for DIV 9 and changed into NBM 
Plus without glutamate. Synaptic integrity experiments were carried out 
on DIV 21 so that fine synaptic structures were present. All cell media 
was supplemented with antibiotic mixture (Invitrogen, CA). Media was 
completely changed one day after plating and partially changed every 
2–3 d. 
2.4. Calcium imaging 
Live cell imaging was conducted on frontal cortex neuronal cultures 
using a Zeiss Axio Observer Z.1 inverted microscope (20× objective) 
with an automated, computer-controlled stage encoder with environ-
mental control (37 ◦C, 95% humidity, 5% CO2). The cell permeant 
acetoxymethyl (AM) ester-linked [Ca2+]i indicator fura-2 AM (Kd = 145 
nM; 2.5 uM, Molecular Probes, Eugene, OR) was used for measuring 
[Ca2+]i and diluted in Brainphys culture media. MCM was added 1 min 
after experiment start. Neurons were imaged for a 30 min period. Using 
ZEN 2010 blue Edition software, images were acquired with a MRm 
digital camera (Zeiss, MN) at a frame rate of 0.2 Hz during the first 5 
min, and 0.033 Hz from 5 min to 30 min. Relative fluorescence ratio 
images were acquired at 340/380 nm excitation and 510 nm emission 
wavelengths. Conversion to [Ca2+]i was calculated according to an 
equation described previously (Grynkiewicz et al., 1985). Regions of 
interest (ROIs) were manually assigned to neuronal somata. Due to the 
heterogeneity among neurons, the mean ± standard error of the mean 
(SEM) values for changes in [Ca2+]i were computed comparing indi-
vidual neurons before and at specific intervals during treatment using a 
repeated-measure analysis of variance (ANOVA). Quantitative analyses 
of [Ca2+]i levels in neuronal somata were performed on 10–15 randomly 
selected neurons per treatment per experiment. At least three indepen-
dent experiments were run for each treatment group. 
2.5. Immunocytochemistry 
DIV 21 neuronal cultures grown on glass coverslips were fixed in 4% 
paraformaldehyde for 10 min. Dendritic structures were visualized using 
Acti-stain 488 phalloidin (Cytoskeleton, Denver, CO) to label mature 
and immature pre-synaptic structures. Neurons were then counter-
stained with Hoechst 33342 for 3 min and mounted using ProLong Gold 
(Molecular Probes, OR). PBS 1× washes were applied between each 
step. Cells were visualized as immunofluorescent image z-stacks ac-
quired using a Zeiss LSM 700 laser scanning confocal microscope 
equipped with a 20× objective (Zeiss, MN). Randomly selected regions 
containing phalloidin-positive neuronal processes were selected and 
orthogonal projections were taken from each image stack. Phalloidin- 
positive (F-actin) staining of neuronal dendrites has been shown to 
generate discrete “hot spots” or bright “puncta”, which represent a 
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variety of dendritic structures, including mature spines, non-spiny syn-
apses and immature spines (Li et al., 2016). Thus, puncta, as the 
analyzed particles, were defined as objects between 0.3 and 1.2 μm, 
similar to what has been described previously (Li et al., 2016; Roscoe 
et al., 2014). Selection threshold criterion was determined by the size of 
punctate structures found in the randomly collected images (minimal 
pixel threshold: 20). Square ROIs were randomly assigned to areas 
containing positive fluorescent signal using ImageJ. Mean gray pixel 
values and number of phalloidin-positive punctate structures contained 
in each ROI were computed using built-in ImageJ functions. 10 images 
were analyzed per treatment group, with 22 ROIs randomly assigned to 
each. Based on the calcium imaging data only the four main treatment 
groups were included (MCM Control, MCM Tat 100 nM, MCM PF3845 
100 nM + Tat, MCM CID 100 nM + PF3845 + Tat), with excluding drug 
only conditions. Gray pixel values and puncta count were used as 
dependent factors. 
2.6. ELISA and multiplex quantification of cytokines/chemokines and 
MMP-9 
Levels of cytokines/chemokines and MMPs in MCM were quantified 
using the following products, CYTOMAG-70 K (cytokine panel, Milli-
pore, MA), MMMP3MAG-79 K (proMMP-9, Millipore, MA), and Pico-
Kine EK0466 (MMP-9, Boster Bio, CA). Levels of both the inactive 
proMMP-9 and cleaved/activated MMP-9 were quantified. Experi-
ments were carried out as detailed in the manufacturer’s instructions 
except all standards were run in Brainphys to match the MCM samples. 
For ELISAs a BioTek Synergy HT multi-mode plate reader (BioTek, VT) 
was used to measure absorbance and for multiplexes a Bio-Rad Bio-Plex 
200 (Bio-Rad, CA) reader was used to measure mean fluorescence in-
tensity. At least three independent experiments were run per treatment 
group. Concentrations of MCP-1/CCL2 and MMPs were used as depen-
dent factors. 
2.7. Fractal analysis of microglial morphology 
As microglial function is well-correlated with microglia morphology 
(i.e. ramified/resting compared to unramified/activated microglia) we 
employed fractal analysis as a quantitative method to assess the 
morphology of microglia based on complexity (Karperien and Jelinek, 
2015; Morrison et al., 2017). Phase images of DIV 14 live microglial cells 
were acquired using Zeiss Axio Observer Z.1 inverted microscope 
equipped with a 20× objective. 10 randomly selected regions, per 
treatment group, containing microglia were selected for analysis. All 
images were processed using ImageJ as previously described (Young and 
Morrison, 2018). In brief, a bandpass and unmask filter were applied to 
images followed by the despeckle function. The threshold function was 
used to make cells into solid, single object representations. Cells that 
were difficult to delineate from bordering cells were excluded from 
analysis. Gaps in the borders of cells were filled in manually. Fractal 
analysis of individual microglial cells was carried out using the box- 
counting method provided with the FracLac plug-in for ImageJ. 
Fractal dimension (DF) and lacunarity (Λ) are measures of microglial 
morphological complexity. Fractal dimension quantifies the number of 
repeating complex pattern within the cell’s shape (Karperien and Jeli-
nek, 2015). Thus, activated (more circular shaped) microglia are less 
complex and have a lower fractal dimension compared to ramified/ 
resting microglia. On the other hand, lacunarity describes the degree of 
heterogeneity that exists in a cell’s shape. Activated ameboid microglia 
are expected to be more homogenous with more similarly sized gaps and 
little rotation variance in their morphology, and thus have low lacu-
narity. Ramified/less activated microglia tend to show more heteroge-
neity with many different sized gaps and notable rotational variance, 
and thus have higher lacunarity (Karperien and Jelinek, 2015). The ROIs 
used for analysis were identical for all cells. Around 15 cells were 
analyzed per image. Fractal dimension and lacunarity were used as 
dependent factors. 
2.8. Liquid chromatography tandem mass spectrometry 
Microglia (post 24 h drug treatment) were aspirated and washed 
with PBS 1× to remove residual culture media. Cells were suspended in 
250 μL of 70% methanol and flash frozen in liquid nitrogen. Details 
regarding sample preparation can be found in the Supplementary 
Methods section. In brief, solid phase extraction was performed to enrich 
for molecules of interest followed by drying with N2 and reconstitution 
in 200 μL of resuspension buffer (7:1.5:1.5 0.1% acetic acid:acetonitrile: 
isopropanol). LC/MS/MS analysis of endocannabinoids was performed 
as described previously (Gouveia-Figueira and Nording, 2015) with 
some modifications (for details see Supplementary Methods). Briefly, 
mass spectrometric analysis was performed on an Agilent 6490 triple 
quadrupole mass spectrometer in positive ionization mode. Quantitation 
of endocannabinoids was achieved using a general isotope dilution 
strategy. Calibration standards were analyzed over a range of concen-
trations from 0.2–40 pg on column for all of the ethanolamides. At least 
three independent experiments were run per treatment group. Concen-
trations of AEA (pg/mL) was used as the dependent factor. 
2.9. Statistical analysis 
Data were analyzed using analysis of variances (ANOVAs) followed 
by Bonferroni’s post hoc test as appropriate (SPSS Statistics, Version 25, 
IBM). Violations of compound symmetry in repeated-measures ANOVAs 
for the within-subjects factors (i.e., comparing time points) were 
addressed by using the Greenhouse-Geisser degrees (pGG) of freedom 
correction factor (Greenhouse and Geisser, 1959). An alpha level of p <
0.05 was considered significant for all statistical tests. Statistics not 
shown in the text were found to be non-significant. ω2 was provided as a 
measure of effect size. Data are expressed as the mean ± SEM. All ex-
periments and data analyses were carried out by experimenters blind to 
treatment condition. 
3. Results 
3.1. Calcium imaging 
3.1.1. Tat-treated microglia produce MCM that provokes neurotoxic 
calcium responses in neurons and this effect is blocked by PF3845 
pretreatment 
To understand the role of FAAH inhibition and Tat in mediating 
microglial neurotoxicity, we investigated [Ca2+]i responses of frontal 
cortex neuron cultures to MCMs derived from PF3945- and/or Tat- 
treated microglia in the presence or absence of different cannabinoid 
or non-cannabinoid receptor antagonists (Fig. 1). Application of MCM 
Tat onto neurons caused a significant increase in [Ca2+]i and this effect 
was not present when applying MCM derived from microglia co-treated 
with PF3845 and Tat or when applying MCM heat inactivated Tat 
(Fig. 1A & B). A two-way ANOVA showed a significant main effect for 
both, time [F(35, 7315) = 16.0, pGG < 0.001] and treatment [F(4, 209) 
= 105.6 p < 0.001], and a significant treatment x time interaction [F 
(140, 7315) = 12.1, pGG < 0.001] (Fig. 1B). A one-way ANOVA con-
ducted on the last 10 min revealed a significant treatment effect [F(4, 
209) = 35.4, p < 0.001, ω2 = 0.404] with MCM Tat 100 nM significantly 
increasing [Ca2+]i compared to all other groups (p < 0.001; Fig. 1B′). 
Note, Tat’s neurotoxic and PF3845’s neuroprotective effects are specific 
to their action on microglia and not on neurons treated with MCM as 
PF3845 100 nM or Tat 100 nM incubated in culture media for 24 h at 
37 ◦C did not show significant changes in [Ca2+]i levels of frontal cortex 
neurons (Supplementary Fig. 1). 
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3.1.2. GPR18 mediates PF3845 ablation of neurotoxic effects of Tat 
treated MCM on neuronal [Ca2+]i 
Using selective CB1R and CB2R antagonists (SR141716 and 
SR144528, respectively), we assessed if these cannabinoid receptors 
mediated PF3845 blockade of MCM neurotoxicity (Fig. 1D & E; also see 
Supplementary Fig. 2 for time course data). As shown in Fig. 1D, the 
CB1R was not necessary to block MCM-mediated neurotoxicity. A one- 
way ANOVA conducted on the last 10 min revealed a significant treat-
ment effect [F(3,196) = 45.5, p < 0.001, ω2 = 0.400], with SR141716 
100 nM failing to significantly block the effect of PF3845 (MCM SR141 
+ PF3845 + Tat vs. MCM Control, MCM PF3845 + Tat; p > 0.05). Please 
see Supplementary Fig. 2A for the time course data. 
Further, results also show the lack of CB2R involvement in mediating 
PF3845’s neuroprotective effects (Fig. 1E). A one-way ANOVA con-
ducted on the last 10 min revealed a significant treatment effect [F 
(3,196) = 46.2, p < 0.001, ω2 = 0.405], with results mirroring what was 
found for CB1R antagonism. Please see Supplementary Fig. 2B for the 
time course data. 
We next assessed the role of GPR18 using the selective antagonist 
CID (Fig. 1F). A one-way ANOVA conducted on the last 10 min revealed 
a significant treatment effect [F(3,195) = 38.0, p < 0.001, ω2 = 0.358], 
with CID 100 nM blocking the protective effect of PF3845 (MCM CID +
PF3845 + Tat vs. MCM Control, MCM PF3845 + Tat; p < 0.001). Please 
see Supplementary Fig. 2C for the time course data. These findings 
suggest that the neuroprotective effect of PF3845 is GPR18-dependent, 
which is also confirmed when further testing the role of GPR18 by 
incubating microglia with increasing concentrations of the GPR18 se-
lective agonist, NAGly (Supplementary Fig. 3). NAGly significantly 
blunted MCM Tat increases in neuronal [Ca2+]i levels in a 
concentration-dependent manner, with the highest concentration 
completely blocking this effect. Additionally, using the selective GPR55 
receptor antagonist ML193, data indicated that 100 nM ML193 failed to 
block PF3845’s effect and although ML193 1 μM did block the neuro-
protective effects of PF3845, this concentration also significantly 
enhance neuronal [Ca2+]i levels in isolation, making it difficult to 
clearly conclude a role of GPR55 in PF3845 microglial neuroprotection 
Fig. 1. (A) Pseudocolor images of neuronal ratiometric calcium imaging comparing frontal cortex neurons (DIV 7–11) treated with MCM Control or MCM Tat 
conditions over 30 min. (B-B′) MCM Tat 100 nM caused significant increases in [Ca2+]i levels while MCM PF3845 + Tat caused no significant changes over 30 min 
(B), which is also supported by the last 10 min of calcium assessment (B′), indicating that PF3845 100 nM blocked MCM Tat effects. Additionally, MCM heat 
inactivated Tat (100 nM) did not elicit any significant [Ca2+]i response. (C) MCM Tat-induced increases in [Ca2+]i levels are significantly downregulated by PF3845 
indicated by the MCM PF3845 + Tat condition. (D) Incubation with the CB1R antagonist, SR141 (100 nM), failed to block PF3845’s neuroprotective effect as seen in 
the MCM SR141 + PF3845 + Tat condition for the last 10 min of the time course data. (E) Likewise, the CB2R antagonist, SR144 (100 nM), failed to block PF3845’s 
neuroprotective effect as seen in the MCM SR144 + PF3845 + Tat condition for the last 10 min of the time course data. (F) Interestingly, the GPR18 antagonist, CID 
(100 nM), significantly blocked the neuroprotective effects of PF3845 in the MCM CID + PF3845 + Tat condition for the last 10 min of the time course data where the 
change in [Ca2+]i was similar to the MCM Tat condition, suggesting that GPR18-related activity was necessary for the observed protective effect. Statistical sig-
nificance was assessed by ANOVAs followed by Bonferroni’s post hoc tests. Bonferroni’s post hoc test were conducted on the last 10 min of the time course data (bar 
graphs); *p < 0.001 vs. MCM Control, #p < 0.05 vs. MCM Tat, $p < 0.05 vs. MCM antagonists + Tat; φp < 0.001 vs. MCM PF3845 + Tat (at least three independent 
experiments). Scale bars = 50 um. MCM, microglia conditioned media; hiTat, heat inactivated Tat; SR141, SR141716A (CB1R antagonist); SR144, SR144528 (CB2R 
antagonist); CID, CID-85469571 (GPR18 antagonist). Please see Supplementary Fig. 2 for the actual time course data of the CB1R, CB2R and GPR18 antagonists 
experiments over a 30 min time period. 
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(Supplementary Fig. 4). 
3.1.3. FAAH KO microglia show a GPR18-mediated neuroprotective 
phenotype 
We compared the neurotoxicity of MCM derived from FAAH KO 
microglia to FAAH WT microglia to further assess the role of FAAH in 
regulating Tat-mediated microglial neurotoxicity (Fig. 2). A two-way 
ANOVA revealed a significant main effect for time [F(35, 7000) =
48.2, pGG < 0.001] and treatment [F(4, 200) = 66.0, p < 0.001], and a 
significant treatment x time interaction [F(140, 7000) = 10.9, pGG <
0.001]. A one-way ANOVA conducted on the last 10 min revealed a 
significant treatment effect [F(4,200) = 71.7, p < 0.001, ω2 = 0.535]. 
MCM Tat 100 nM significantly increased neuronal [Ca2+]i levels 
compared to control conditions (MCM FAAH WT vs. MCM FAAH WT +
Tat, p < 0.001; MCM FAAH WT vs. MCM FAAH KO + Tat, p = 0.003; 
MCM FAAH WT vs. MCM FAAH KO + CID + Tat, p < 0.001). Particularly 
noteworthy, the MCM FAAH WT + Tat and MCM FAAH KO + CID + Tat 
groups elicited significantly higher neuronal [Ca2+]i levels than MCM 
FAAH KO and MCM FAAH KO + Tat groups (p < 0.001), suggesting the 
neuroprotective effect of FAAH KO in microglia is GPR18 dependent. 
3.2. Quantification of dendritic punctate structure following MCM 
challenge 
3.2.1. PF3845 blocks MCM-mediated degeneration of dendritic spine 
punctate structures through a GPR18-dependent mechanism 
As PF3845 significantly blocked neuronal [Ca2+]i production of 
MCM derived from Tat treated microglia over a 30 min time period via 
GPR18-mediated mechanisms, we were interested in whether this effect 
would replicate for long-term events, i.e. when looking at synaptoden-
dritic injury, which plays an essential role in HAND pathogenesis. Thus, 
we examined the effects of PF3845 on murine microglial-mediated Tat 
neurotoxicity and potential GPR18-mechanisms involvement after 24 h 
by staining for phalloidin positive (F-actin) dendritic structures (Fig. 3). 
As numbers of phalloidin-positive puncta reflects a balance among 
active synapses (excitatory and inhibitory), actin dynamics, and synapse 
stability (Zhang and Benson, 2001), changes in dendritic F-actin rich 
structures suggest alterations in synaptic integrity and connectivity. 
Using ImageJ we randomly assigned ROIs to quantify the number of 
punctate structures present on frontal cortex neurons stained with green 
fluorescent phalloidin (Fig. 3A & B). A one-way ANOVA assessing 
changes in mean gray pixel value [F(3,876) = 56.1, p < 0.001, ω2 =
0.158] and puncta count [F(3,876) = 208.0, p < 0.001, ω2 = 0.414] 
revealed a significant treatment effect for both measurements (Fig. 3C & 
D). MCM Tat treatment significantly reduced both gray pixel value and 
puncta count compared to the control condition (MCM Control vs. MCM 
Tat, p < 0.001), while PF3845 blocked this neurotoxic effect (MCM Tat 
vs. MCM PF3845 + Tat, p < 0.001). Administration of CID prevented 
both of these protective effects (MCM PF3845 + Tat vs. MCM CID +
PF3845 + Tat, p < 0.001). It is also noteworthy that incubation with 
PF3845 significantly enhanced both mean gray pixel value and puncta 
count compared to control (MCM Control vs. MCM PF3845, p ≤ 0.001). 
Altogether these data suggest that PF3845 blocks Tat toxicity by 
decreasing overall F-actin structure and specifically dendritic puncta 
number. 
3.3. ELISA and multiplex 
In order to assess the presence and concentration of neurotoxic 
agents in our experimental MCM treatments we used multiplex assays to 
examine a range of cytokine and chemokine related molecules, while an 
ELISA was used to specifically quantify levels of MMP-9 (Fig. 4). All 
experiments were conducted on MCM harvested from microglial cul-
tures 24 h following treatment with Tat 100 nM. Significant levels of 
IFNγ, IL-1β, IL-4, IL-6, IL-10, and TNF-α were not found above the 
detection threshold of the assay (data not shown). 
3.3.1. PF3845 with Tat significantly downregulates levels of MCP-1/CCL2 
found in MCM 
We found that PF3845 pretreatment alongside Tat significantly 
decreased levels of MCP-1/CCL2 compared to both MCM Control and 
MCM Tat conditions (Fig. 4A). A one-way ANOVA revealed a significant 
main effect of treatment [F(3,20) = 30.5, p < 0.001, ω2 = 0.787]. MCP- 
1/CCL2 levels were significantly decreased in the MCM PF3845 + Tat 
group compared to MCM Control and MCM Tat groups (p < 0.001). 
Treatment with CID 100 nM blocked this effect (MCM CID + PF3845 +
Tat vs. MCM Control, MCM Tat; p > 0.05). Note, that pretreating 
microglia with the MCP-1 inhibitor bindarit 300 μM before Tat exposure 
Fig. 2. Live cell calcium imaging experiments of frontal cortex neurons (DIV 7–11) treated with MCM derived from FAAH WT and FAAH KO microglia over a 30 min 
time period. The MCM FAAH KO + Tat condition induced significantly less [Ca2+]i levels than the MCM FAAH WT + Tat condition indicating that decreased FAAH 
activity reduced the neurotoxicity of the MCM. Likewise, the MCM FAAH KO + CID + Tat condition displayed significantly higher levels of neuronal [Ca2+]i 
compared to the MCM FAAH KO + Tat condition suggesting that this observed neuroprotective effect was dependent on GPR18 activity. Statistical significance was 
assessed by ANOVAs followed by a Bonferroni’s post hoc test that was conducted on the last 10 min of the time course data (bar graph); *p < 0.05 vs. MCM FAAH WT, 
#p < 0.05 vs. MCM FAAH WT + Tat, $p < 0.05 vs. MCM FAAH KO + CID + Tat (at least three independent experiments). MCM, microglia conditioned media; WT, 
wildtype; KO, knockout. 
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shows attenuation of MCM Tat-induced [Ca2+]i levels in frontal cortex 
neurons (Supplementary Fig. 5). 
3.3.2. PF3845 blunts Tat protein enhancement of proMMP-9 and MMP-9 
levels in MCM in a GPR18-dependent manner 
Tat significantly enhanced levels of inactive proMMP-9 and cleaved/ 
activated MMP-9 compared to the control condition and PF3845 blunted 
this effect via a GPR18 based mechanism (Fig. 4B & C). A one-way 
ANOVA revealed a significant main effect of treatment for proMMP-9 
[F(3,20) = 209.5, p < 0.001, ω2 = 0.963] and MMP-9 [F(3,15) =
91.4, p < 0.001, ω2 = 0.935]. MCM levels of proMMP-9 and MMP-9 were 
significantly increased by Tat incubation and this effect was attenuated 
by PF3845 (MCM Control vs. MCM Tat vs. MCM PF3845 + Tat; p <
0.001). Incubation with CID showed that PF3845’s effect on MMP levels 
was tied to the GPR18 receptor (MCM Tat vs. MCM CID + PF3845 + Tat, 
p > 0.05). Similar to the effects seen with bindarit 300 μM, pretreating 
microglia with MMP-9 inhibitor I 150 nM before Tat exposure demon-
strated an attenuation of MCM Tat-induced [Ca2+]i levels in frontal 
cortex neurons, suggesting that both MCP-1/CCL2 and MMP-9 at least 
partially mediate MCM Tat-induced toxicity (Supplementary Fig. 5). 
3.4. Microglial fractal analysis 
3.4.1. PF3845 treatment significantly increases fractal dimension (DF) and 
significantly decreases lacunarity (Λ) of primary murine microglia 
Microglia have been shown to take on a wide range of morphological 
features which have been associated with distinct functions, thus we 
were interested in whether morphological changes can be observed in 
cultured microglia. As significant upregulated levels of MCP-1/CCL2, 
inactive proMMP-9, and cleaved/activated MMP-9 were noted in 
MCM Tat, which was significantly downregulated by MCM PF3845 
pretreatment, we were interested in whether changes can be observed in 
microglia morphology as they have been associated with distinct func-
tions. Thus, using live phase images of 24 h treated microglial cells at 
DIV 14 we conducted fractal analysis using ImageJ to determine fractal 
dimension (DF) and lacunarity (Λ) as measures of microglial morpho-
logical complexity (Fig. 5). A one-way ANOVA assessing DF and Λ 
revealed a significant treatment effect for both measurements [F(5,599) 
= 19.4, p < 0.001, ω2 = 0.132 and F(5,600) = 18.5, p < 0.001, ω2 =
0.126, respectively]. Whereas no effect was noted for Tat treatment, 
PF3845 significantly enhanced DF compared to control (Control vs. 
PF3845, PF3845 + Tat; p < 0.001) and significantly lowered Λ 
compared to control (Control vs. PF3845, PF3845 + Tat; p < 0.001). CID 
blocked both of these effects. 
3.5. LC/MS/MS 
3.5.1. PF3845 significantly enhances levels of AEA in primary murine 
microglia 
To confirm the effects of PF3845 as a FAAH enzyme inhibitor, LC/ 
MS/MS was used to determine the expression of AEA and other pre-
dominant substrates of FAAH in MCM conditions derived from microglia 
treated with PF3845 100 nM ± Tat 100 nM for 24 h (Fig. 6). 
As expected PF3845 led to a significant elevation of AEA levels in 
MCM conditions (Fig. 6). A two-way ANOVA detected a significant 
treatment effect of MCM PF3845 [F(1,11) = 270.3, p < 0.001], and 
MCM Tat [F(1,11) = 7.2, p = 0.200], but no significant interaction effect 
[F(1,11) = 1.4, p > 0.05]. A one-way ANOVA assessing treatment effect 
[F(4,10) = 72.8, p < 0.001, ω2 = 0.950] found a significant difference 
between all PF3845 treatment groups and all non-PF3845 treated 
groups (MCM Control, MCM Tat vs. all MCM PF3845 conditions). 
PF3845 100 nM, regardless of treatment group, caused a roughly two- 
fold increase of AEA levels in MCM conditions. FAAH inhibition also 
led to significant increases in other fatty acids (i.e., docosahexaenoyl 
ethanolamide (DHEa) and oleoylethanolamide (OEA); Supplementary 
Fig. 7). 
4. Discussion 
MCM derived from Tat-treated microglia significantly increased 
neuronal [Ca2+]i levels, comparable to the increase seen with direct Tat 
treatment (Brailoiu et al., 2008; Hermes et al., 2018) and with HIV-1 
Fig. 3. (A & B) Pseudocolor images of phalloidin-stained frontal cortex 
neuronal cultures (DIV 21) treated with various MCM conditions for 24 h. (A′ & 
B′) Inset images are depicted on the main image by white boxes and the white 
arrows denote phalloidin stained punctate structures. (C) MCM Tat treatment 
significantly decreased average gray pixel value of phalloidin staining while 
MCM PF3845 + Tat enhanced average gray pixel value of phalloidin staining, 
relative to MCM Control treatment. MCM CID + PF3845 + Tat did not cause the 
protective effect seen in MCM PF3845 + Tat treatment, suggesting that PF3845 
treatment blocks the loss of actin in dendritic structures induced by Tat in MCM 
via a GPR18-related mechanism. (D) MCM Tat treatment significantly 
decreased phalloidin labelled puncta number while MCM PF3845 + Tat 
enhanced phalloidin labelled puncta number, relative to MCM Control treat-
ment. This suggests that PF3845 protected and increased the number of actin- 
containing synaptic structures against Tat-related neurotoxicity through 
microglia. MCM CID + PF3845 + Tat did not cause the protective effect seen in 
MCM PF3845 + Tat treatment, indicating that GPR18 appears to be a necessary 
receptor in this PF3845 neuroprotective effect. Statistical significance was 
assessed by ANOVAs followed by Bonferroni’s post hoc tests; *p < 0.001 vs. 
MCM Control, #p < 0.001 vs. MCM Tat, $p ≤ 0.001 vs. MCM CID + PF3845 +
Tat. Scale bars: Primary = 100 μm, Inset = 30 μm. MCM, microglial conditioned 
media; CID, CID-85469571. 
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Fig. 4. (A) MCM Tat caused a significant increase in MCP-1/CCL2 levels compared to MCM Control treatment while incubation with PF3845 blocked this increase 
and further decreased MCP-1/CCL2 levels compared to control. Antagonizing GPR18 with CID blocked these PF3845-mediated decreases in MCP-1/CCL2 as seen in 
the MCM CID + PF3845 + Tat condition. (B) MCM Tat caused a significant increase in proMMP-9 levels compared to control and incubating with PF3845 blocked 
this effect. Antagonizing GPR18 with CID blocked this PF3845-mediated decrease in proMMP-9 as seen in the MCM CID + PF3845 + Tat condition. (C) MCM Tat 
caused a significant increase in MMP-9 levels compared to control and incubation with PF3845 blocked this effect. Antagonizing GPR18 with CID blocked the 
PF3845-mediated decrease in MMP-9 as seen in the MCM CID + PF3845 + Tat condition. Collectively, these data suggest that Tat enhanced the excretion of 
neurotoxins, while PF3845 blunted this effect at least partially through GPR18-related activity. Statistical significance was assessed by ANOVAs followed by Bon-
ferroni’s post hoc tests; *p < 0.05 vs. MCM Control, #p < 0.05 vs. MCM Tat, $p < 0.05 vs. MCM CID + PF3845 + Tat. MCM, microglial conditioned media; CID, 
CID-85469571. 
Fig. 5. (A) An overlay of a phase image of cultured 
microglia with outlines of randomly selected micro-
glia processed for ImageJ FracLac analysis. (A′) Phase 
image of cultured microglia showing a range of 
amoeboid and branched morphologies. (A′′) Outlines 
of randomly selected microglia processed for ImageJ 
FracLac analysis with an inset image that is repre-
sented on the primary image by a black box showing 
microglial ruffles. (C) Microglia treated with PF3845 
and PF3845 + Tat treatment conditions demonstrated 
a significant increase in fractal dimension (DF) 
compared to other treatment conditions, indicating 
microglia morphology following PF3845 treatment is 
more associated with an intermediate activation state 
and less with the activated amoeboid state. (D) 
Microglia treated with PF3845 and PF3845 + Tat 
treatment conditions demonstrated a significant 
decrease in lacunarity (Λ) compared to other treat-
ment conditions, suggesting that the PF3845 treated 
microglia have more overall morphological homoge-
neity. No effects were noted for Tat treatment 
potentially as microglia grown in culture in vitro 
under control conditions reside in a more amoeboid 
phenotype/shape. Statistical significance was 
assessed by ANOVAs followed by Bonferroni’s post 
hoc tests; *p < 0.05 vs. Control. Scale Bars: Primary 
= 100 μm, Inset = 30 μm. CID, CID-85469571.   
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conditioned media (Meeker et al., 2016). The 24 h time point for MCM 
collection was selected to avoid the effect of drugs/proteins applied to 
stimulate the microglia from being carried from microglial treatment to 
neuronal cultures. Considering that Tat-induced MCM was a mixture of 
different factors excreted from microglia, we were unable to conclude on 
specific mechanisms of neuronal calcium dysregulation, nonetheless, 
upregulated MCP-1/CCL2 and MMP-9 might be a contributing factor to 
the upregulation of intracellular calcium in our neuronal cultures. MCP- 
1/CCL2 upregulates NMDA receptor function (Zhou et al., 2016) in a 
fashion similar to what has been described in earlier reports of Tat- 
mediated neurotoxicity (Fitting et al., 2014; Haughey et al., 2001). 
Likewise, MMP-9 enhances NMDA receptor surface trafficking, which 
may alter receptor functioning (Michaluk et al., 2009). Remarkably, 
PF3845 pretreatment of microglia completely abolished Tat-induced 
MCM’s changes in neuronal [Ca2+]i. The current study examined re-
ceptor mechanism of action through the employment of selective an-
tagonists for CB1R, CB2R, GPR18, and GPR55. Here we show that this 
neuroprotective effect was independent of CB1R, CB2R, and GPR55, but 
reliant on GPR18 activity. In addition to showing that the GPR18 
antagonist, CID, blocked this neuroprotective effect of PF3845, incu-
bation of microglia with increasing concentrations of the GPR18 selec-
tive agonist, NAGly, confirmed the role of this receptor in MCM Tat- 
induced neurotoxicity, with the highest concentration of NAGly 
completely blocking this effect (Supplementary Fig. 3). It is also 
important to consider that NAGly can inhibit FAAH, particularly at high 
μM concentrations (Grazia Cascio et al., 2004). A simplified schematic 
summarizes our findings in Fig. 7. 
Even though a range of cannabinoid receptor ligands such as AEA, 2- 
AG, Δ9-tetrahydrocannabinol (THC), and cannabidiol (CBD) bind to 
both GPR55 and GPR18 (Lauckner et al., 2008; McHugh et al., 2012), 
GPR55 did not show a clear role in PF3845 microglial neuroprotection 
(Supplementary Fig. 4). It is also noteworthy that GPR55 antagonism 
alone could be anti-inflammatory (Saliba et al., 2018) in some models of 
microglial signaling, though the present study did not directly assess this 
action. Further, a GPR18-dependent neuroprotective effect similar to 
PF3845 was found in FAAH KO microglia, implying that higher fatty 
acid amide content, such as AEA, ameliorated microglial neurotoxicity 
(Fig. 2). The findings that the neuroprotective effects were based on 
GPR18, but not CB2R, were particularly surprising given the prominent 
role of CB2R activation on neuroprotective and anti-inflammatory acti-
vation in microglia (Ehrhart et al., 2005; Malek et al., 2015; Maresz 
et al., 2005). A positive control experiment using lipopolysaccharide 
(LPS) to increase MCP-1/CCL2 levels in our microglia cultures demon-
strated MCM MCP-1/CCL2 downregulation when the CB2R agonist HU- 
308 was used in combination with LPS 1 μg/mL challenge (Chhor et al., 
2013; Presley et al., 2015, Supplementary Fig. 6) suggesting that our 
microglia express CB2Rs. An important factor to keep in mind when 
comparing these different studies is that variations in cannabinoid re-
ceptor expression can be tied to microglial activation states and 
signaling. Differences in CB2R expression have been shown previously, 
with LPS-activated macrophages having low CB2R expression, while 
interferon gamma (IFNγ) treatment greatly enhances microglial CB2R 
(Ashton and Glass, 2007). Also, a recent study has shown that CB2R and 
GPR18 readily form heterodimers and display negative-crosstalk and 
cross-antagonism, suggesting that extricating the individual roles of 
these receptors in modulating microglial activity may be more difficult 
than originally expected (Reyes-Resina et al., 2018). 
Glia-based neuroinflammation has been linked to neuronal damage/ 
death and specifically to the progression of synaptodendritic injury in 
HIV-related disease (Block et al., 2007; Bruce-Keller, 1999; Green et al., 
2019; Liu et al., 2013; Lu et al., 2011; Nath et al., 1999; Takeuchi, 2010), 
which in turn strongly correlates with HAND symptom severity (Ellis 
et al., 2007; Masliah et al., 1992; Masliah et al., 1997). Dendritic spines 
are small, actin rich structures that are paramount in healthy neuronal 
signaling and are highly sensitive to changes in intracellular calcium 
(Higley and Sabatini, 2008; Hotulainen and Hoogenraad, 2010; Maha-
jan and Nadkarni, 2019). We have previously shown that Tat directly 
disrupts healthy dendritic morphology and PF3845 partially blocked 
this effect (Hermes et al., 2018). The loss of overall synaptic connectivity 
in DIV 21 MCM-treated neurons was quantified via overall actin staining 
and number of phalloidin-positive punctate structures. Based on our 
calcium findings, it was not surprising that MCM Tat significantly 
reduced overall actin staining and puncta count, while treating micro-
glia with PF3845 blocked this effect (Fig. 3). Specifically, it has been 
shown previously that a 2–4-fold upregulation from baseline [Ca2+]i 
levels at around 100 nM to ~200–400 nM for an extended amount of 
time (>5 min) precede profound changes in neuronal morphology as 
well as neuronal loss in primary CNS neuron cultures (Fitting et al., 
2014; Kouzoukas et al., 2013; Tolar et al., 1999). Calcium dysregulation 
is a common theme in several neurodegenerative diseases (Imamura 
et al., 2016; Verma et al., 2018; Wojda et al., 2008; Zündorf and Reiser, 
2011) and chronic neuroinflammation correlates with loss of neuronal 
calcium equilibrium (Oliveira et al., 2014; Sama and Norris, 2013; 
Zündorf and Reiser, 2011). Previous studies have shown that modu-
lating NMDA receptor activity can prevent Tat-induced synapse loss 
(Raybuck et al., 2017) and cannabinoids can achieve this through 
similar mechanisms (Kim et al., 2008). 
Tat appears to be a major component of HAND progression as it is 
expressed early in HIV-1 infection (Fisher et al., 1986; Nicoli et al., 2013) 
and is detectable in appreciable levels in diagnosed patients (Henderson 
et al., 2019). Further, Tat has been shown to drive proinflammatory 
signaling and immune dysregulation (Ben Haij et al., 2015; Gandhi et al., 
2009). Microglia exposed to Tat become activated and release various 
signaling molecules that can be ultimately deleterious to neuronal sur-
vival and proper functioning (Jin et al., 2012; Lu et al., 2011; Thangaraj 
et al., 2018). As the proinflammatory cytokines TNF-α, IL-1β and IL-6 
were below the lower detection threshold in the present study, no con-
clusions could be made on the involvement of these mediators. However, 
suprathreshold levels of MCP-1/CCL2 and pro-form/cleaved MMP-9 
Fig. 6. Concentrations of AEA in MCM were assessed using LC/MS/MS analysis 
following 24 h of PF3845, Tat and/or CID exposure to cultured microglia. All 
MCM conditions treated with PF3845 had significantly enhanced levels of AEA 
compared to MCM Control and MCM Tat. This suggests that PF3845 was 
effective in inhibiting microglial FAAH’s ability to degrade AEA. No effects on 
AEA levels were noted when CID was added to MCM PF3845 + Tat, indicating 
that blocking AEA’s activity on GPR18 receptors had no effect on AEA levels 
itself. Statistical significance was assessed by ANOVAs followed by a Bonfer-
roni’s post hoc test; *p < 0.05 vs. MCM Control, #p < 0.05 vs. MCM Tat. MCM, 
microglial conditioned media; CID, CID-85469571. 
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were detected in MCM, significantly increased following Tat treatment 
(Fig. 4), and partially mediated Tat-induced toxicity (Supplementary 
Fig. 5). MCP-1/CCL2 is a key mediator of microglial migration following 
activation (Park et al., 2001), is upregulated following Tat treatment 
(Eugenin et al., 2005, Fig. 4A), and is capable of enhancing neuronal 
excitability via CCR2 (Zhou et al., 2011). Disruptions in the balance of 
MMP expression have been linked with a wide range of neurodegenera-
tive and neurodevelopmental diseases (Reinhard et al., 2015) and MMP- 
9, in particular, plays a key role in regulating the structural plasticity of 
dendritic spines (Stawarski et al., 2014). Additionally, increases in MMP- 
9 production have been shown in HIV-related non-human and human 
studies (Webster and Crowe, 2006), and has been linked with enhanced 
neurotoxicity in models of neurodegeneration (Jourquin et al., 2003; 
Mizoguchi et al., 2009). Pretreatment with 100 nM PF3845 significantly 
reduced levels of MCP-1/CCL2 and MMPs (with MCP-1/CCL2 being 
reduced below control), while CID partially blocked this effect, suggest-
ing that GPR18 serves an important role in regulating activated microglia 
(Fig. 4). The finding that Tat + PF3845 produces less MCP-1/CCL2 than 
PF3845 pretreatment alone suggests that PF3845 might exacerbate its 
effect in the presence of a disease state. As outlined in the present study 
MCM Tat exposure is associated with neuronal damaging effects, indi-
cated by upregulation of intracellular calcium and decrease in puncta 
number, thus PF3845 might overcompensate by greatly changing the 
signaling behavior of glia and driving MCP-1/CCL2 levels below what is 
seen with baseline or with PF3845 alone. A previous study has demon-
strated that WIN55,212 is able to decrease TNF-α levels in brain slices of 7 
d old rats to lower levels than those found in controls (Fernandez-Lopez 
et al., 2006). Further, a compensatory effect of the endocannabinoid 
system in disease states has been suggested previously by the upregula-
tion of the CB1R and endocannabinoid system activity in experimental 
models of Parkinson’s disease as well as neuroHIV (Brotchie, 2003; Ja-
cobs et al., 2019). 
Considering the heightened levels of these molecules following Tat 
treatment of our microglial cultures and the resulting neurotoxicity from 
MCM incubation of neurons, this study lends additional support to both 
MCP-1/CCL2 and MMP-9 playing an important role, alongside other 
molecules, in driving HAND related pathology. Likewise, PF3845 could 
be useful in reducing factors that promote HAND progression. 
Microglia have been shown to take on a wide range of morphological 
features which have been associated with distinct functions. Primary 
microglia exist mostly in an activated state, making them a good model 
for neurodegenerative disorders in which this activated morphology has 
been observed (Timmerman et al., 2018). In the present study, it was 
determined that the majority of the microglia that make up the cultures 
used in the present study fall into the unramified/activated morpho-
logical state (Karperien et al., 2013; Karperien and Jelinek, 2015). Using 
Fig. 7. (A) Shows the effects of treatment 
conditions on microglia morphology. Tat 
does not show any effects on fractal dimen-
tion (DF) and lacunarity (Λ) whereas PF3845 
via GPR18 increases DF and decreases Λ, 
which is associated with a less activated 
microglia state and more overall morpho-
logical homogeneity, respectively. (B) Shows 
the soluble factors released from treated 
microglia into the microglial conditioned 
media (MCM). MCM conditions derived from 
Tat treated microglia (MCM Tat) show 
upregulated proinflammatory responses with 
increased levels in MCP-1/CCL2, MMP-9, 
and proMMP-9. In contrast, MCMs derived 
from microglia pretreated with PF3845 
(MCM PF3845) show increased AEA levels 
by inhibiting the catabolic FAAH enzyme via 
GPR18-related mechanisms, which results in 
anti-inflammatory responses by decreasing 
MCP-1/CCL2, MMP-9, and proMMP-9 levels. 
(C) Shows neuronal changes that occur when 
frontal cortex neurons are treated with MCM 
conditions derived from treated microglia. 
MCM Tat increases neuronal Ca2+ dysregu-
lation and synaptodendritic damage whereas 
MCMs derived from microglia pretreated 
with PF3845 alongside Tat (MCM PF3845 +
Tat) results in reduction of Ca2+ dysregula-
tion and synaptodendritic damage via 
GPR18-related mechanisms. Λ, lacunarity; 
Ca2+, calcium; CID-85469571, GPR18 
antagonist; DF, fractal dimension.   
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a box-counting method for fractal analysis and found that microglia 
treated with PF3845 took on a distinct profile of DF and Λ compared to 
untreated glia (Fig. 5). PF3845-treated microglia had significantly 
higher DF and lower Λ as compared to non-treated cells. As microglia 
proceed from ramified to unramified states both DF and Λ decrease and 
increase again as cells “re-ramify” (Karperien and Jelinek, 2015). Thus, 
based on DF our data indicate that PF3845-mediated changes in our 
microglia are moving away from a stereotypical activated morpholog-
ical state. Similarly, another study showed that the effects of another 
FAAH inhibitor, URB597, decreased production of proinflammatory 
molecules accompanied by increases in DF and decreases in Λ following 
ethanol-induced activation of microglia in mouse hippocampus (Rivera 
et al., 2018). This finding further suggests that the observed decrease in 
Λ is related to selective FAAH inhibition, with the caveat that the former 
study focused on ramified and intermediate state microglia. These 
PF3845-related morphological changes were blocked by CID, providing 
further evidence of the involvement of GPR18. GPR18-induced changes 
in microglial morphology have been previously reported, with NAGly 
incubation enhancing a branched morphology over an ameboid state 
(McHugh et al., 2014). In contrast, no effects of Tat treatment were 
noted on DF and Λ, highly likely due to the fact that microglia grown in 
culture in vitro are more activated than under in vivo conditions and 
reside in a more amoeboid phenotype/shape (Caldeira et al., 2014; Lai 
et al., 2013). 
FAAH inhibitors represent a promising pharmaceutical treatment for 
HIV-induced neurotoxicity and HAND progression given decreased 
FAAH activity leads to heightened levels of AEA and other anti- 
inflammatory fatty acid amides (Booker et al., 2012). Based on our 
findings, decreased microglial neurotoxicity likely relies on enhance-
ment of AEA signaling (Fig. 6). Microglia express GPR18, which is 
stimulated by AEA (McHugh et al., 2012); however, the EC50 is in the 
low micromolar range. NAGly, proposed endogenous ligand for GPR18, 
was unlikely involved in the current results as one of its major biosyn-
thesis pathways is FAAH-dependent and FAAH inhibition decreases 
NAGly levels (Bradshaw et al., 2009). Regardless, NAGly possesses 
powerful inflammation-resolving properties dependent on GPR18 ac-
tivity (Burstein et al., 2011), with an EC50 of 44.5 nM (McHugh et al., 
2012). Compared to earlier experiments with neuronal cultures (Hermes 
et al., 2018), our microglial cultures produced roughly 2-fold greater 
levels of AEA in control conditions. This is similar to earlier reports that 
described microglia as producing the bulk of endocannabinoids as 
compared to other cell types in the brain (Walter et al., 2002; Walter 
et al., 2003). It is important to note that these levels are significantly 
below the EC50 levels for GPR18 activity described before, suggesting 
that the observed GPR18-related neuroprotective effect may be depen-
dent on multiple lipids regulated by FAAH. Altogether, these findings 
further our understanding of the underlying mechanism of FAAH inhi-
bition for the potential treatment of microglial neurotoxicity in condi-
tions like HAND or other neurodegenerative diseases. 
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